Harvard Bioscience Added to NASDAQ Biotechnology Index
HOLLISTON, Mass., Nov 21, 2003 (BUSINESS WIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), announced today that it will be added to the NASDAQ Biotechnology Index (NBI) effective with the market open on Monday, November 24, 2003.
The NASDAQ Biotechnology Index originated in 1993 and includes pharmaceutical and biotechnology companies as classified by the FTSE Global Classification System. The Index, which is ranked on a semi-annual basis in May and November, serves as the basis for the iShares NASDAQ Biotechnology Index Fund (IBB). All securities in the NASDAQ Biotechnology Index are listed on the NASDAQ National Market and must meet minimum eligibility requirements including market capitalization and average daily trading volume. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit www.nasdaq.com.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily scientific instruments, used to accelerate drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. HBIO sells its products to thousands of researchers in 100 countries though its direct sales force, a 1,000-page catalog, various specialty catalogs and through its distributors, including Amersham Biosciences and PerkinElmer. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, Austria and Belgium with sales facilities in France, Canada and Japan.
For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site, http://www.harvardbioscience.com.
SOURCE: Harvard Bioscience, Inc.
Harvard Bioscience, Inc.
Investor information:
David Green, 508-893-8999
dgreen@harvardbioscience.com
Disclaimer:
The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrances or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience’s web site. For Harvard Bioscience’s most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at http://www.sec.gov.